The Translational Breast Cancer Research Consortium was well represented at the 2017 SABCS Meeting. Presentations included:

Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (TBCRC 023); Abstract #P2-09-12

Molecular Determinants of Post-Mastectomy Breast Cancer Recurrence (TBCRC 027); Abstract # P3-04-01

Molecular Subtyping of Male Breast Cancer by the International Male Breast Cancer Program (IMBC): EORTC 10085/ TBCRC 029/BIG 2­07/NABCG/BOOG 2009­04; Abstract #PD7-12

Clinical and Biological Characterization of Male Breast Cancer (MBC) EORTC 10085/ TBCRC 029/ BOOG 2013-02/ BIG 2-07: Baseline Results from the Prospective Registry; Abstract # P5-23-01

Quality of Life (QoL) in Male Breast Cancer (BC): Prospective Study of the EORTC10085/ TBCRC 029/BIG/NABCG International Male BC Program; Abstract #P5-23-02

TBCRC 039 Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer; Abstract #OT3-05-01

TBCRC 044 A Randomized Phase II Study of Pembrolizumab in Combination with Carboplatin versus Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease; Abstract #OT1-02-03